Associated Papers
Structural basis of MPL activation by thrombopoietin.
Mafi A et al.
Blood Vessels, Thrombosis & Hemostasis, 2024
Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin.
Sarson-Lawrence KTG et al.
Nature Communications, 2024
In Silico Evaluation of Coding and Non-Coding nsSNPs in the Thrombopoietin Receptor (MPL) Proto-Oncogene: Assessing Their Influence on Protein Stability, Structure, and Function.
Al-Nakhle HH et al.
Current Issues in Molecular Biology, 2023
Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis.
Tsutsumi N et al.
Cell, 2023
CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients.
Germeshausen M et al.
Haematologica, 2021
Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F et al.
Journal of Thrombosis and Haemostasis : Jth, 2018
The genomic landscape of pediatric myelodysplastic syndromes.
Schwartz JR et al.
Nature Communications, 2017
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.
Varghese LN et al.
Frontiers in Endocrinology, 2017
Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.
Plo I et al.
Frontiers in Endocrinology, 2017
Identification of MPL R102P Mutation in Hereditary Thrombocytosis.
Bellanné-Chantelot C et al.
Frontiers in Endocrinology, 2017
The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.
Stockklausner C et al.
Blood, 2015
Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
Pecci A
International Journal of Hematology, 2013
Congenital amegakaryocytic thrombocytopenia.
Geddis AE
Pediatric Blood & Cancer, 2011
F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
Fox NE et al.
Experimental Hematology, 2010
Advances in the understanding of congenital amegakaryocytic thrombocytopenia.
Ballmaier M et al.
British Journal of Haematology, 2009
Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature.
Fox NE et al.
Experimental Hematology, 2009
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease.
Germeshausen M et al.
Human Mutation, 2006